Aurora's international medical cannabis business bolstered its results, with European sales doubling quarter-over-quarter.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) announced its financial results for the fiscal 2025 second quarter. Total revenue rose year-over-year and the company has a positive outlook for the ...
Key Takeaways Marijuana stocks fell Wednesday after a ballot measure in Florida that would have legalized recreational ...
CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical ...
Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expand sales of its medical ...
Inc. (TSX: ACB) reported strong results in its fiscal Q2 2025 earnings, posting a 29% year-over-year increase in total revenue, reaching $81.1 million compared to $63.1 million in ...
A ballot measure to legalize recreational pot failed to reach the required 60 percent threshold for passage, and publicly listed companies' shares dropped after a major market was closed to them.
Several of the well-known players are gaining in today's trading session; a welcome win for long term cannabis investors.
Aurora Cannabis' profit rose in its fiscal second quarter thanks to a strong performance from its medical cannabis unit.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback